Large Austrian Medical Centre publishes study results on component utilization and patient safety after adoption of platelet pathogen inactivation.
The Medical University Hospital in Innsbruck has evaluated the influence of the INTERCEPT™ Blood System for platelets on component utilization and patient safety. The effectiveness of conventional vs. INTERCEPT™-treated platelets was analyzed during two 21-month periods before and after implementation of pathogen inactivation.
Results of the study were published recently in Vox Sanguinis - The Internal Journal of Transfusion Medicine.
The information on this site is not country-specific, and may contain information that is outside the approved indications for the country in which you are located. Use of INTERCEPT Plasma or Platelets is contraindicated in patients with a history or allergic response to amotosalen or psoralens. Consult instructions for use for indications, contraindications, warnings, and precautions.